AstraZeneca PLC (AZN)

63.59 -0.42 (-0.66%) At close: 04:00PM EST

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
https://www.astrazeneca.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 83,500

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Pascal Soriot D.V.M., M.B.A.	CEO & Executive Director	6.02M	N/A	1959
Dr. Aradhana Sarin M.D.	CFO & Executive Director	3.44M	N/A	1975
Ms. Pam P. Cheng	EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board	N/A	N/A	1971
Mr. Andrew P. Barnett	Head of Investor Relations	N/A	N/A	N/A
Mr. Jeffrey Pott	CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board	N/A	N/A	N/A
Gonzalo Vina	Head of Global Media Relations	N/A	N/A	N/A
Dr. Menelas Pangalos Ph.D.	EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board	N/A	N/A	1967
Dr. Ruud Dobber Ph.D.	Executive Vice-President of BioPharmaceuticals Business Unit	N/A	N/A	N/A
Dr. Susan Mary Galbraith M.D., Ph.D.	Executive Vice President of Oncology Research & Development	N/A	N/A	1966
Mr. Leon Wang	Executive VP of International & China President	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Corporate governance

AstraZeneca PLC’s ISS governance QualityScore as of 1 December 2023 is 2. The pillar scores are Audit: 7; Board: 1; Shareholder rights: 1; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.